Мобилизация и исходы после венозной окклюзии (MOVE)
MOVE - Мобилизация и исходы после ВЕНОЗНОГО закрытия - Проспективный регистр реальных исходов/использования/доказательств для сосудистого устройства закрытия MYNX CONTROL™ VENOUS 6F-12F
The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in patients who have undergone endovascular procedures in a real-world setting.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
The study is a single-arm, prospective, multi-center, observational, real-world registry of venous access site closures utilizing MYNX CONTROL™ VENOUS VCD 6F-12F following endovascular procedures. The study will enroll approximately 300 subjects in approximately 15 study sites in the United States.
Тип исследования
Тип исследования
Регистрация (Действительный)
Регистрация
Контакты и местонахождение
Места учебы
-
-
California
-
Los Angeles, California, Соединенные Штаты, 90048
- Cedars Sinai Medical Center
-
Palo Alto, California, Соединенные Штаты, 94304
- Stanford University School of Medicine
-
-
Colorado
-
Littleton, Colorado, Соединенные Штаты, 80210
- South Denver Cardiology
-
-
Florida
-
Orlando, Florida, Соединенные Штаты, 32803
- AdventHealth Orlando
-
-
Illinois
-
Glenview, Illinois, Соединенные Штаты, 60026
- Glenbrook Hospital
-
-
Kansas
-
Overland Park, Kansas, Соединенные Штаты, 66211
- KC Heart and Rhythm Institute
-
-
Kentucky
-
Lexington, Kentucky, Соединенные Штаты, 40503
- Baptist Health Lexington
-
-
North Carolina
-
Raleigh, North Carolina, Соединенные Штаты, 27607
- North Carolina Heart & Vascular Research, LLC
-
-
Washington
-
Bellevue, Washington, Соединенные Штаты, 98004
- Overlake Medical Center
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
- Ребенок
- Взрослый
- Пожилой взрослый
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
The study includes patients who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.
Описание
Inclusion Criteria
- Able and willing to provide informed consent and to complete a follow-up visit at 14 ± 7 days post-procedure.
- Individuals undergoing catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs.
- Individuals who are candidates to have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.
- At the time of enrollment, the Investigator deems the subject a candidate for same-day discharge (SDD) per standard of care (no procedure related events/complications e.g., no new pericardial effusion, post-procedure diuresis not needed, etc.).
Exclusion Criteria
- Presence of bruit, palpable aneurysm, significant candida or groin infection.
- Prior to closure, presence of hematoma in the accessed limb.
- Currently involved in any other clinical trial that may interfere with the outcomes of this study as determined by the Investigator.
- Planned use of other closure devices or techniques other than MYNX CONTROL™ VENOUS VCD 6F-12F.
- Life expectancy <12 months.
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Количество групп / когорт
Когорты и вмешательства
Группа / когортаГруппа / когорта |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
MCV VCD Treatment
Subjects who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU. |
The MYNX CONTROLTM VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing 6F to 12F procedural sheaths, with single or multiple access sites in one or both limbs. MCV VCD is designed to achieve femoral vein hemostasis via delivery of the GRIP TECHNOLOGY™ sealant (an extravascular, water-soluble synthetic hydrogel), using a balloon catheter in conjunction with a standard procedural sheath. The sealant is made of a polyethylene glycol (PEG) material which expands upon contact with subcutaneous fluids to seal the venotomy and is resorbed by the body within 30 days. The MCV VCD is supplied with a 10ml locking syringe used for balloon inflation and deflation. The catheter shaft has a silicone lubricant to facilitate insertion and withdrawal into compatible sheaths. |
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Rate of patients with same day discharge (SDD) and without subsequent hospitalization/intervention for access-site complications
Временное ограничение: From time of index procedure through end of following day (within 48 hours)
|
Rate of patients who successfully received a study device at all access sites and had SDD without subsequent hospitalization/intervention for access-site complications either same day post-discharge or the next day |
From time of index procedure through end of following day (within 48 hours)
|
|
Rate of access-site complications
Временное ограничение: From time of study device introduction at first access site through 14 days post-procedure
|
Rate of access-site complications, assessed per standard of care, through 14 days post-procedure, including:
|
From time of study device introduction at first access site through 14 days post-procedure
|
Другие показатели результатов
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Time to Ambulation
Временное ограничение: From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
Defined as elapsed time (in hours) between removal of the final MCV VCD and when subject stands and walks 20 feet without evidence of rebleeding from any femoral venous access site. |
From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
|
Time to Discharge
Временное ограничение: From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)
|
Defined as the elapsed time (in minutes) between removal of the final MCV VCD and when the subject is discharged from the hospital, as recorded on the discharge order. |
From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)
|
|
Time to Hemostasis
Временное ограничение: From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
Defined as elapsed time (in minutes) between removal of each MCV VCD and first observed and confirmed venous hemostasis (per access site analysis). |
From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
|
SDD sustained MCV VCD success
Временное ограничение: From end of index procedure through 14 days post-procedure
|
Defined as the proportion of subjects who did not require hospital intervention within 14 days post-procedure due to access site-related complications |
From end of index procedure through 14 days post-procedure
|
|
Device success evaluated at the end of the procedure
Временное ограничение: End of index procedure
|
Defined as the ability to deploy the delivery system and deliver the PEG component to achieve hemostasis at each access site |
End of index procedure
|
|
Procedural Success
Временное ограничение: From end of index procedure through 14 days post-procedure
|
Defined as the attainment of final hemostasis at all venous access sites without major venous access site closure-related complications through 14 days |
From end of index procedure through 14 days post-procedure
|
|
Procedural Time
Временное ограничение: Index procedure
|
Defined as time of first sheath insertion until the time of removal of final MCV VCD. |
Index procedure
|
|
Recovery room time
Временное ограничение: From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)
|
Defined as elapsed time (in minutes) between when the subject is transferred to recovery and when the subject is discharged from the hospital, as recorded on the discharge order. |
From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)
|
|
Analysis of Cost Effectiveness - Comprehensive summary of clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes
Временное ограничение: From start time of index procedure through 14 days post-procedure
|
An analysis of cost effectiveness will be performed based on a summary of key clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes |
From start time of index procedure through 14 days post-procedure
|
|
Incidence of urinary catheter usage
Временное ограничение: From start time of index procedure through end time of index procedure
|
Number/rate of patients with urinary catheters used during the procedure |
From start time of index procedure through end time of index procedure
|
|
Incidence of protamine usage
Временное ограничение: From start time of index procedure through end time of index procedure
|
Incidence of protamine usage during the procedure |
From start time of index procedure through end time of index procedure
|
|
Medication Usage
Временное ограничение: From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)
|
Rate of patients who are administered anti-platelet, anti-coagulant, anti-thrombotic, local anesthetic, protamine or pain medication |
From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)
|
Соавторы и исследователи
Спонсор
Спонсор
Соавторы
Соавторы
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Действительный)
Первичное завершение
Завершение исследования (Действительный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- P25-8302
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
продукт, произведенный в США и экспортированный из США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .